News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly More insights from ODYSSEY OUTCOMES: News round-up from ACC.19 What was the PCSK9 news at this year’s Congress? News round-up from ACC.19 Did someone say “Beyond LDL-cholesterol”?Diabetes does not affect the efficacy of inclisiran ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Available now - first two decks focusing on the main results from FOURIER and ODYSSEY OUTCOMES – two landmark trials in PCSK9 inhibition

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

ACC Scientific Sessions 2019

What was the PCSK9 news at this year’s Congress?

ODYSSEY OUTCOMES: Lipoprotein(a) analysis

More insights from ODYSSEY OUTCOMES

News from AHA 2018

News from ESC Congress 2018

Most viewed

ODYSSEY MONO ODYSSEY ALTERNATIVE New Simon Broome register data: Mortality benefit of statins in men with familial hypercholesterolaemia but women lag behind Cardiovascular risk in familial hypercholesterolaemia: Consider also the presence of subclinical disease Study reinforces the importance of cascade screening in families with familial hypercholesterolaemia What was the PCSK9 news at this year’s Congress? News round-up from ACC.19 Novel lipoprotein(a) antisense therapy looks good: now to test the lipoprotein(a) hypothesis Familial hypercholesterolaemia-causing mutations prevalent in ACS VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) Alirocumab effective against the spectrum of mutations causative for familial hypercholesterolaemia

Most viewed

ODYSSEY MONO

PCSK9 Forum Inhibitors and Health Economics

The value of PCSK9 inhibition in very high risk patients is a Hot Topic in the light of recent data from the ODYSSEY OUTCOMES Economics Study. How do these data relate to the current clinical pathway used in the European setting?

PCSK9 Forum Editor Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital London, UK) puts the results in context.
Watch the video

Perspective on the ODYSSEY OUTCOMES Economic Study
Watch the video

PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
Watch the video

Hot Topics

Coronary artery calcium in familial hypercholesterolaemia

Coronary artery calcium may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. This noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk.

Read the report

VIDEO: Is coronary artery calcium a risk assessment too in FH?
Watch the video

VIDEO: Severe FH: how to define?
Watch the video

VIDEO: ESC/EAS Task Force guidance for PCSK9 inhibitors
Watch the video

From the Editors

Did someone say “Beyond LDL-cholesterol”?

PCSK9 Forum Editor Professor John Chapman (Pitié-Salpétrière University Hospital, and Sorbonne University, Paris, France) discusses how ‘OMICS’ technologies could provide a precision medicine approach to managing non-LDL lipids.

Read the report